Improvement of cerebral blood flow by olprinone, a phosphodiesterase-3 inhibitor, in mild heart failure

Cerebrovasc Dis. 2003;16(4):396-401. doi: 10.1159/000072563.

Abstract

Cerebral blood flow (CBF) is reduced in heart failure (HF). For the treatment of acute HF, a phosphodiesterase-3 inhibitor, olprinone (OL), yields an increase in myocardial contractility and a decrease in arterial afterload. During a 15-min intravenous infusion of OL (0.2 microg/kg/min), regional CBF at 6 sites of each cerebral cortex was examined using technetium-99m-ethylcysteinate dimer brain SPECT in 18 HF patients and 7 age-matched normal subjects. The baseline CBF was significantly reduced in HF (43.0 +/- 3.9 ml/min/100 g) compared to that in normal subjects (48.0 +/- 4.6 ml/min/100 g, p < 0.01). The baseline CBF showed a significant negative correlation with the increase in CBF during the OL infusion in HF (r = -0.38, p < 0.01) and normal subjects (r = -0.65, p < 0.01). The percent increase in CBF was significantly greater in HF (13.7%) than in normal subjects (9.8%, p < 0.046). In patients with HF, the CBF of the cerebral cortex was decreased, but was increased by OL infusion.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Blood Pressure / drug effects
  • Cerebral Cortex / blood supply
  • Cerebral Cortex / diagnostic imaging
  • Cerebral Cortex / drug effects
  • Cerebrovascular Circulation / drug effects*
  • Female
  • Heart Failure / diagnostic imaging
  • Heart Failure / physiopathology*
  • Heart Rate / drug effects
  • Humans
  • Imidazoles / pharmacology*
  • Male
  • Middle Aged
  • Phosphodiesterase Inhibitors / pharmacology*
  • Pyridones / pharmacology*
  • Radionuclide Imaging
  • Severity of Illness Index

Substances

  • Imidazoles
  • Phosphodiesterase Inhibitors
  • Pyridones
  • olprinone